Tempus Publications

npj Genomic Medicine, Tempus-authored — BRCA-mutant cancers often develop therapeutic resistance through several mechanisms. Here, we report a case of pathogenic germline BRCA2-driven breast cancer monitored for disease progression and acquired resistance using longitudinal multi-tissue genomic testing. Briefly, genomic testing was performed throughout the course of diseas...

Circulation, Tempus-authored — BACKGROUND: Atrial fibrillation (AF) is associated with substantial morbidity, especially when it goes undetected. If new-onset AF could be predicted, targeted screening could be used to find it early. We hypothesized that a deep neural network could predict new-onset AF from the resting 12-lead ECG and t...

ASCO Genitourinary Cancers Symposium 2021, Tempus-authored — Background: African American (AA) men have higher prostate cancer (PC) incidence and PC-specific mortality than non-AA men. Socioeconomic/healthcare access and environmental factors contribute to the disparity in clinical outcomes. Moreover, AA PC exhibits increased inflammatory and immune response signaling, which ma...

ASCO Genitourinary Cancers Symposium 2021, Tempus-authored — Background: Sarcomatoid carcinoma is a rare and aggressive histologic variant pattern of prostate cancer with morphologic features associated with both mesenchymal and epithelial tissue elements. While sarcomatoid cancer can be found concurrently with adenocarcinoma in untreated specimens, it is most often encounte...

ASCO Genitourinary Cancers Symposium 2021, Tempus-authored — Background: The largest US cancer health disparity exists in prostate cancer (PC), with African American (AA) men having: ~1.6-1.8-fold higher risk of developing PC; younger age and more advanced stage at diagnosis; increased risk of recurrence after radical prostatectomy; and...

World Conference on Lung Cancer 2020, Tempus-authored — Introduction Immune checkpoint inhibitors (ICI) provide limited benefit in patients with EGFR-, ALK- or ROS1-positive lung adenocarcinoma (LUAD), while patients with BRAF- and KRAS-positive LUAD demonstrate better responses. To understand the differential response to ICI...

Nature Communications, Tempus-authored — Several immunotherapy clinical trials in recurrent glioblastoma have reported long-term survival benefits in 10–20% of patients. Here we perform genomic analysis of tumor tissue from recurrent WHO grade IV glioblastoma patients acquired prior to immunotherapy intervention. We report that very low tumor mutation burden is associ...

ASCO Gastrointestinal Cancers Symposium 2021, Tempus-authored —  Background: Molecular changes and associated acquired resistance of rectal tumors following chemoradiotherapy (CRT) have not been well studied. We aimed to examine CRT-induced molecular changes and prognostic associations in rectal cancer patients (pts) undergoing preoperative CRT followed by surgery. Methods: A paire...

ASCO Gastrointestinal Cancers Symposium 2021, Tempus-authored — Background: Cholangiocarcinoma (CCA) is a target-rich disease. Despite this, treatment guidelines lack recommendations for broad molecular profiling in CCA to identify potentially actionable targets. Furthermore, comparative data assessing similarities and differences in actionable ctDNA and tissue based genomic biomarkers remain li...

Clinical Breast Cancer, Tempus-authored — Objective/Background We performed a retrospective analysis of longitudinal real-world data (RWD) from patients with breast cancer to replicate results from clinical studies and demonstrate the feasibility of generating real-world evidence. We also assessed the value of transcriptome profiling as a complementary tool for determi...